Literature DB >> 22237045

Work disability rates in RA. Results from an inception cohort with 24 years follow-up.

Elena Nikiphorou1, Daphne Guh, Nick Bansback, Wei Zhang, Josh Dixey, Peter Williams, Adam Young.   

Abstract

OBJECTIVE: To explore rates of and reasons for work disability in an early RA cohort with median 10 years follow-up.
METHODS: One thousand four hundred and sixty patients with early RA (<2 years symptom duration) and no prior DMARD therapy were recruited from nine rheumatology outpatient departments across the UK between 1986 and 1998. Standard clinical, laboratory and radiological assessments were recorded at 6-monthly and yearly intervals. Assessment of employment included details of type and hours of paid work. The main outcomes investigated were rates of and main reasons for work cessation, analysed by age of onset of RA (<45, 45-60 years) and year of recruitment to the study (before or after 1992).
RESULTS: Maximum follow-up was 24 years, median 10 years. Of 647 patients in paid work at baseline, the majority were <60 years old (91%). The estimated probability of stopping work due to RA was highest in patients with older age of onset (45-60 years) who were recruited before 1992, but improved in those recruited from 1992 to 1998 (P < 0.01). There was no difference seen over the study recruitment years in younger age of onset patients.
CONCLUSION: Work loss related to RA occurred much earlier than for other reasons, especially in the first 5 years of RA, but improved in the later recruitment period. Work disability is multifactorial, and the gradual changes in therapies used over time in this cohort may be one explanation for the secular differences seen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237045     DOI: 10.1093/rheumatology/ker401

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

Review 1.  Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.

Authors:  Natalie McCormick; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  Curr Rheumatol Rep       Date:  2017-10-30       Impact factor: 4.592

2.  Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study.

Authors:  Shohei Anno; Yuko Sugioka; Kentaro Inui; Masahiro Tada; Tadashi Okano; Kenji Mamoto; Tatsuya Koike
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

Review 3.  Economics of stratified medicine in rheumatoid arthritis.

Authors:  Sean Gavan; Mark Harrison; Cynthia Iglesias; Anne Barton; Andrea Manca; Katherine Payne
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

4.  Etanercept (Enbrel®) alternative storage at ambient temperature.

Authors:  Edel Shannon; Joanne Daffy; Heather Jones; Andrea Paulson; Steven M Vicik
Journal:  Clin Pharmacol       Date:  2017-07-21

5.  Workability and Muscle Strength in Patients With Seropositive Rheumatoid Arthritis: Survey Study Protocol.

Authors:  Carolin Berner; Ludwig Erlacher; Michael Quittan; Karl Heinrich Fenzl; Thomas Ernst Dorner
Journal:  JMIR Res Protoc       Date:  2017-03-02

6.  Work Ability and Employment in Rheumatoid Arthritis: A Cross-Sectional Study on the Role of Muscle Strength and Lower Extremity Function.

Authors:  Carolin Berner; Sandra Haider; Igor Grabovac; Thomas Lamprecht; Karl Heinrich Fenzl; Ludwig Erlacher; Michael Quittan; Thomas Ernst Dorner
Journal:  Int J Rheumatol       Date:  2018-08-01

7.  Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort.

Authors:  Daniel F McWilliams; Sneha Varughese; Adam Young; Patrick D Kiely; David A Walsh
Journal:  Rheumatology (Oxford)       Date:  2013-11-15       Impact factor: 7.580

8.  Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis.

Authors:  Kalle Mattila; Frank Buttgereit; Risto Tuominen
Journal:  Rheumatol Int       Date:  2014-05-29       Impact factor: 2.631

9.  Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.

Authors:  Elena Nikiphorou; Sam Norton; Adam Young; Lewis Carpenter; Josh Dixey; David Andrew Walsh; Patrick Kiely
Journal:  Ann Rheum Dis       Date:  2016-03-15       Impact factor: 19.103

10.  Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.

Authors:  Evo Alemao; Maiwenn J Al; Annelies A Boonen; Matthew D Stevenson; Suzanne M M Verstappen; Kaleb Michaud; Michael E Weinblatt; Maureen P M H Rutten-van Mölken
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.